Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 596


RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

J Natl Cancer Inst. 2018 Mar 12. doi: 10.1093/jnci/djy029. [Epub ahead of print] No abstract available.


Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.


Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.

Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, Tonn JC, Zielinski C.

ESMO Open. 2018 Jan 26;3(1):e000262. doi: 10.1136/esmoopen-2017-000262. eCollection 2018. Review.


Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.

Mauracher LM, Posch F, Martinod K, Grilz E, Däullary T, Hell L, Brostjan C, Zielinski C, Ay C, Wagner DD, Pabinger I, Thaler J.

J Thromb Haemost. 2018 Mar;16(3):508-518. doi: 10.1111/jth.13951. Epub 2018 Feb 7.


ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO).

Ohe Y, Zielinski C.

ESMO Open. 2017 Aug 4;2(3):e000240. doi: 10.1136/esmoopen-2017-000240. eCollection 2017. No abstract available.


Reply to: Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks or Modern Cancer Therapies.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2017 Nov 17. doi: 10.1093/annonc/mdx747. [Epub ahead of print] No abstract available.


Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region.

Rolfo C, Zielinski CC.

Ann Thorac Med. 2017 Oct-Dec;12(4):219-220. doi: 10.4103/atm.ATM_225_17. No abstract available.


Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.

Pavo N, Raderer M, Goliasch G, Wurm R, Strunk G, Cho A, Novak JF, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider ST, Parschalk B, Scheithauer W, Pirker R, Kiesewetter B, Pacher R, Zielinski C, Hülsmann M.

Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. eCollection 2017 Oct 6.


Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Review.


Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.


Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI.

ESMO Open. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017.


Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2018 Feb 1;29(2):521-522. doi: 10.1093/annonc/mdx649. No abstract available.


ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.


Hemodynamics of Pericardial Aortic Valves: Contemporary Stented versus Stentless Valves in a Matched Comparison.

Christ T, Holinski S, Zhigalov K, Zielinski CB, Grubitzsch H.

Ann Thorac Cardiovasc Surg. 2017 Dec 20;23(6):298-303. doi: 10.5761/atcs.oa.17-00061. Epub 2017 Sep 8.


Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC - A single center case series.

Brandl A, Zielinski CB, Raue W, Pratschke J, Rau B.

Ann Med Surg (Lond). 2017 Aug 9;22:7-11. doi: 10.1016/j.amsu.2017.08.009. eCollection 2017 Oct.


One year of ESMO Open: Cancer Horizons-where are we going from here?

Zielinski C.

ESMO Open. 2017 Jan 23;1(6):e000153. doi: 10.1136/esmoopen-2016-000153. eCollection 2016. No abstract available.


Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.


Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.


The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.


Human T cell immune surveillance: Phenotypic, functional and migratory heterogeneity for tailored immune responses.

Zielinski CE.

Immunol Lett. 2017 Oct;190:125-129. doi: 10.1016/j.imlet.2017.08.001. Epub 2017 Aug 4. Review.


The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.

Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC.

ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.


CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.

Preusser M, Berghoff AS, Thallinger C, Zielinski C.

ESMO Open. 2017 Jun 8;2(2):e000194. doi: 10.1136/esmoopen-2017-000194. eCollection 2017.


Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.

Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M.

Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.


Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.

Bianconi D, Heller G, Spies D, Herac M, Gleiss A, Liebmann-Reindl S, Unseld M, Kieler M, Scheithauer W, Streubel B, Zielinski CC, Prager GW.

Sci Rep. 2017 Jul 7;7(1):4851. doi: 10.1038/s41598-017-04743-0.


Spatiotemporal reorganization of the reading network in adult dyslexia.

Cavalli E, Colé P, Pattamadilok C, Badier JM, Zielinski C, Chanoine V, Ziegler JC.

Cortex. 2017 Jul;92:204-221. doi: 10.1016/j.cortex.2017.04.012. Epub 2017 Apr 24.


Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.


Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, Piccart M, de Vries EGE.

Ann Oncol. 2017 Aug 1;28(8):2031-2032. doi: 10.1093/annonc/mdx200. No abstract available.


Erratum to: Measuring sequences of keystrokes with jsPsych: Reliability of response times and interkeystroke intervals.

Pinet S, Zielinski C, Mathôt S, Dufau S, Alario FX, Longcamp M.

Behav Res Methods. 2017 Jun;49(3):1177-1178. doi: 10.3758/s13428-017-0865-y. No abstract available.


Long-Term Outcome of the Sorin Freedom SOLO Stentless Aortic Valve.

Christ T, Claus B, Zielinski C, Falk V, Grubitzsch H.

J Heart Valve Dis. 2016 Nov;25(6):679-684.


Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.


Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease.

Kieler M, Scheithauer W, Zielinski CC, Chott A, Al-Mukhtar A, Prager GW.

ESMO Open. 2016 Dec 15;1(6):e000084. doi: 10.1136/esmoopen-2016-000084. eCollection 2016.


PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.

Gschwantler-Kaulich D, Tan YY, Fuchs EM, Hudelist G, Köstler WJ, Reiner A, Leser C, Salama M, Attems J, Deutschmann C, Zielinski CC, Singer CF.

PLoS One. 2017 Mar 2;12(3):e0172911. doi: 10.1371/journal.pone.0172911. eCollection 2017.


TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine.

Pascual-Reguant A, Bayat Sarmadi J, Baumann C, Noster R, Cirera-Salinas D, Curato C, Pelczar P, Huber S, Zielinski CE, Löhning M, Hauser AE, Esplugues E.

Mucosal Immunol. 2017 Nov;10(6):1431-1442. doi: 10.1038/mi.2017.5. Epub 2017 Feb 15.


Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.

Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U.

BMC Cancer. 2017 Feb 9;17(1):118. doi: 10.1186/s12885-017-3098-7.


Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.


SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.


Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.


Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.


CSCO joins ESMO Open-Cancer Horizons.

Zielinski CC, Wu YL.

ESMO Open. 2016 Nov 18;1(5):e000120. eCollection 2016. No abstract available.


ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG.

ESMO Open. 2016 Oct 18;1(5):e000100. eCollection 2016. Review.


AIOM chooses ESMO Open-Cancer Horizons as its official journal: a warm welcome from ESMO Open.

Zielinski CC, Pinto C.

ESMO Open. 2016 Jul 1;1(4):e000080. eCollection 2016. No abstract available.


The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.


Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.

Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C.

ESMO Open. 2016 Jun 17;1(4):e000055. eCollection 2016. Review.


Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.


Recent developments and translational aspects in targeted therapy for metastatic breast cancer.

Marhold M, Bartsch R, Zielinski C.

ESMO Open. 2016 May 4;1(3):e000036. eCollection 2016. Review.


Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.


ESMO Open-Cancer Horizons and the future of oncology.

Zielinski CC.

ESMO Open. 2016 Jan 18;1(1):e000008. eCollection 2016. No abstract available.


Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart MJ, de Vries EG.

Ann Oncol. 2016 Nov;27(11):2136-2137. Epub 2016 Aug 29. No abstract available.


Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G.

Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8.


Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome.

Barmeyer C, Schumann M, Meyer T, Zielinski C, Zuberbier T, Siegmund B, Schulzke JD, Daum S, Ullrich R.

Int J Colorectal Dis. 2017 Jan;32(1):29-39. doi: 10.1007/s00384-016-2663-x. Epub 2016 Sep 30.

Supplemental Content

Loading ...
Support Center